Alterations of Serum Neuropeptide Levels and Their Relationship to Cognitive Impairment and Psychopathology in Male Patients with Chronic Schizophrenia

Overview

Journal Schizophrenia (Heidelb)

Date 2024 Jan 3

PMID 38172494

Authors

Wenxi Sun

Tingting Jin

Haidong Yang

Jin Li

Qing Tian

Ju Gao

Ruijie Peng

Guangya Zhang

Xiaobin Zhang

Affiliations

Soon will be listed here.

Abstract

Serum neuropeptide levels may be linked to schizophrenia (SCZ) pathogenesis. This study aims to examine the relation between five serum neuropeptide levels and the cognition of patients with treatment-resistant schizophrenia (TRS), chronic stable schizophrenia (CSS), and in healthy controls (HC). Three groups were assessed: 29 TRS and 48 CSS patients who were hospitalized in regional psychiatric hospitals, and 53 HC. After the above participants were enrolled, we examined the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the blood serum levels of α-melanocyte stimulating hormone (α-MSH), β-endorphin (BE), neurotensin (NT), oxytocin (OT) and substance.P (S.P). Psychiatric symptoms in patients with SCZ were assessed with the Positive and Negative Syndrome Scale. SCZ patients performed worse than HC in total score and all subscales of the RBANS. The levels of the above five serum neuropeptides were significantly higher in SCZ than in HC. The levels of OT and S.P were significantly higher in CSS than in TRS patients. The α-MSH levels in TRS patients were significantly and negatively correlated with the language scores of RBANS. However, the BE and NT levels in CSS patients were significantly and positively correlated with the visuospatial/constructional scores of RBANS. Moreover, the interaction effect of NT and BE levels was positively associated with the visuospatial/constructional scores of RBANS. Therefore, abnormally increased serum neuropeptide levels may be associated with the physiology of SCZ, and may cause cognitive impairment and psychiatric symptoms, especially in patients with TRS.

References

Zak P, Kurzban R, Matzner W . Oxytocin is associated with human trustworthiness. Horm Behav. 2005; 48(5):522-7. DOI: 10.1016/j.yhbeh.2005.07.009. View

Rubin L, Wehring H, Demyanovich H, Carter C, Pournajafi-Nazarloo H, Feldman S . Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women with chronic schizophrenia. Schizophr Res. 2017; 195:409-411. DOI: 10.1016/j.schres.2017.09.041. View

McGonigle P . Peptide therapeutics for CNS indications. Biochem Pharmacol. 2011; 83(5):559-66. DOI: 10.1016/j.bcp.2011.10.014. View

Heinrichs R, Zakzanis K . Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998; 12(3):426-45. DOI: 10.1037//0894-4105.12.3.426. View

Reichenberg A . The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin Neurosci. 2010; 12(3):383-92. PMC: 3181984. View

Ogren S, Kuteeva E, Elvander-Tottie E, Hokfelt T . Neuropeptides in learning and memory processes with focus on galanin. Eur J Pharmacol. 2009; 626(1):9-17. DOI: 10.1016/j.ejphar.2009.09.070. View

Binder E, Kinkead B, Owens M, Nemeroff C . Neurotensin and dopamine interactions. Pharmacol Rev. 2001; 53(4):453-86. View

Volavka J, Davis L, Ehrlich Y . Endorphins, dopamine, and schizophrenia. Schizophr Bull. 1979; 5(2):227-39. DOI: 10.1093/schbul/5.2.227. View

Ebner K, Singewald N . The role of substance P in stress and anxiety responses. Amino Acids. 2006; 31(3):251-72. DOI: 10.1007/s00726-006-0335-9. View

10.

Hokfelt T, Everitt B, Goldstein M . Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons. J Comp Neurol. 1984; 222(4):543-59. DOI: 10.1002/cne.902220407. View

11.

Dickinson D, Ramsey M, Gold J . Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007; 64(5):532-42. DOI: 10.1001/archpsyc.64.5.532. View

12.

Nucifora Jr F, Woznica E, Lee B, Cascella N, Sawa A . Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2018; 131:104257. PMC: 6395548. DOI: 10.1016/j.nbd.2018.08.016. View

13.

Alonso J, Mortier P, Auerbach R, Bruffaerts R, Vilagut G, Cuijpers P . Severe role impairment associated with mental disorders: Results of the WHO World Mental Health Surveys International College Student Project. Depress Anxiety. 2018; 35(9):802-814. PMC: 6123270. DOI: 10.1002/da.22778. View

14.

Feifel D, MacDonald K, Cobb P, Minassian A . Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res. 2012; 139(1-3):207-10. DOI: 10.1016/j.schres.2012.05.018. View

15.

Suzuki T, Remington G, Mulsant B, Uchida H, Rajji T, Graff-Guerrero A . Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012; 197(1-2):1-6. DOI: 10.1016/j.psychres.2012.02.013. View

16.

Zhu R, Wang D, Tian Y, Du Y, Chen J, Zhou H . Sex difference in association between insomnia and cognitive impairment in patients with chronic schizophrenia. Schizophr Res. 2022; 240:143-149. DOI: 10.1016/j.schres.2021.12.045. View

17.

Jauhar S, Johnstone M, McKenna P . Schizophrenia. Lancet. 2022; 399(10323):473-486. DOI: 10.1016/S0140-6736(21)01730-X. View

18.

Jomphe C, Lemelin P, Okano H, Kobayashi K, Trudeau L . Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons. Eur J Neurosci. 2006; 24(10):2789-800. DOI: 10.1111/j.1460-9568.2006.05151.x. View

19.

Kalkstein S, Hurford I, Gur R . Neurocognition in schizophrenia. Curr Top Behav Neurosci. 2011; 4:373-90. DOI: 10.1007/7854_2010_42. View

20.

Creese I, Burt D, Snyder S . Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192(4238):481-3. DOI: 10.1126/science.3854. View